Pharma Lawsuits Escalate

Drugmakers and the Pharmaceutical Research and Manufacturers of America challenge the administration’s use of most-favored-nation pricing and state-linked savings transfers. The central question becomes whether CMS has authority to tie U.S. concessions to foreign price increases without new legislation.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.